Clinical trial fraud is a prevalent issue that demands attention. Although it may be challenging to fathom, it is imperative to address.
Despite the daunting nature of the problem, there is a glimmer of hope on the horizon. According to insiders within the industry, regulatory oversight is intensifying. In 2021, Arun Rao, Deputy Assistant Attorney General at the U.S. Department of Justice, underscored the commitment to focus on identifying and combatting clinical trial fraud in the years ahead.
Various forms of clinical trial fraud exist, ranging from straightforward actions like enrolling ineligible participants to more intricate schemes such as grant fraud, which involves the misappropriation of government-granted funds.
Irrespective of the specific type of fraud in question, sponsors must proactively implement measures to prevent its occurrence. Fortunately, there are several strategies available to uphold due diligence and substantially reduce the risk of fraud.